SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis

FRA:56S1 • FR0013154002

180.95 EUR
-0.15 (-0.08%)
Last: Feb 23, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Overall 56S1 gets a fundamental rating of 4 out of 10. We evaluated 56S1 against 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. 56S1 is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • 56S1 had positive earnings in the past year.
  • In the past year 56S1 had a positive cash flow from operations.
  • 56S1 had positive earnings in 4 of the past 5 years.
  • 56S1 had a positive operating cash flow in 4 of the past 5 years.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • 56S1 has a Return On Assets of 3.36%. This is in the lower half of the industry: 56S1 underperforms 66.67% of its industry peers.
  • 56S1 has a worse Return On Equity (6.55%) than 61.11% of its industry peers.
  • 56S1's Return On Invested Capital of 5.94% is in line compared to the rest of the industry. 56S1 outperforms 44.44% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is in line with the industry average of 9.63%.
  • The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(5.94%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 3.36%
ROE 6.55%
ROIC 5.94%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • With a Profit Margin value of 8.98%, 56S1 perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
  • 56S1's Profit Margin has declined in the last couple of years.
  • With a decent Operating Margin value of 16.63%, 56S1 is doing good in the industry, outperforming 61.11% of the companies in the same industry.
  • 56S1's Operating Margin has declined in the last couple of years.
  • 56S1 has a Gross Margin (45.64%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of 56S1 has declined.
Industry RankSector Rank
OM 16.63%
PM (TTM) 8.98%
GM 45.64%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
  • 56S1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • 56S1 has an Altman-Z score of 4.06. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
  • 56S1 has a better Altman-Z score (4.06) than 77.78% of its industry peers.
  • The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
  • 56S1 has a Debt to FCF ratio of 6.84. This is comparable to the rest of the industry: 56S1 outperforms 55.56% of its industry peers.
  • 56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.50, 56S1 is doing good in the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 6.84
Altman-Z 4.06
ROIC/WACC0.65
WACC9.19%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
  • 56S1 has a worse Current ratio (1.05) than 66.67% of its industry peers.
  • A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.50, 56S1 is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.5
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • 56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.71%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 1.13% on average over the past years.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.78%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.33% on average over the next years. This is quite good.
  • 56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.84% yearly.
EPS Next Y21.28%
EPS Next 2Y21.44%
EPS Next 3Y22.34%
EPS Next 5Y18.33%
Revenue Next Year7.74%
Revenue Next 2Y9.23%
Revenue Next 3Y9.67%
Revenue Next 5Y10.84%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 41.12, the valuation of 56S1 can be described as expensive.
  • 56S1's Price/Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 77.78% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.64, 56S1 is valued quite expensively.
  • A Price/Forward Earnings ratio of 33.91 indicates a quite expensive valuation of 56S1.
  • 72.22% of the companies in the same industry are cheaper than 56S1, based on the Price/Forward Earnings ratio.
  • 56S1 is valuated rather expensively when we compare the Price/Forward Earnings ratio to 27.75, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 41.12
Fwd PE 33.91
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 72.22% of the companies in the same industry are cheaper than 56S1, based on the Enterprise Value to EBITDA ratio.
  • 56S1's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 61.11% of the companies in the same industry.
Industry RankSector Rank
P/FCF 47.02
EV/EBITDA 24.6
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 56S1 does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as 56S1's earnings are expected to grow with 22.34% in the coming years.
PEG (NY)1.93
PEG (5Y)36.45
EPS Next 2Y21.44%
EPS Next 3Y22.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.39%, 56S1 is not a good candidate for dividend investing.
  • 56S1's Dividend Yield is a higher than the industry average which is at 0.44.
  • Compared to an average S&P500 Dividend Yield of 1.80, 56S1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.39%

5.2 History

  • The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1

5.3 Sustainability

  • 56S1 pays out 25.37% of its income as dividend. This is a sustainable payout ratio.
  • 56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.37%
EPS Next 2Y21.44%
EPS Next 3Y22.34%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SARTORIUS STEDIM BIOTECH

FRA:56S1 (2/23/2026, 7:00:00 PM)

180.95

-0.15 (-0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)N/A
Inst Owners11.88%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.61B
Revenue(TTM)N/A
Net Income(TTM)264.50M
Analysts78.95
Price Target246.85 (36.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.39%
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.37%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)-0.19%
PT rev (3m)3.35%
EPS NQ rev (1m)-0.7%
EPS NQ rev (3m)2.5%
EPS NY rev (1m)0%
EPS NY rev (3m)0.65%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)-0.49%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-1.41%
Valuation
Industry RankSector Rank
PE 41.12
Fwd PE 33.91
P/S 5.98
P/FCF 47.02
P/OCF 24.1
P/B 4.36
P/tB N/A
EV/EBITDA 24.6
EPS(TTM)4.4
EY2.43%
EPS(NY)5.34
Fwd EY2.95%
FCF(TTM)3.85
FCFY2.13%
OCF(TTM)7.51
OCFY4.15%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.93
PEG (5Y)36.45
Graham Number64.07
Profitability
Industry RankSector Rank
ROA 3.36%
ROE 6.55%
ROCE 7.46%
ROIC 5.94%
ROICexc 6.26%
ROICexgc 21.64%
OM 16.63%
PM (TTM) 8.98%
GM 45.64%
FCFM 12.71%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 6.84
Debt/EBITDA 2.5
Cap/Depr 112.98%
Cap/Sales 12.09%
Interest Coverage 3.09
Cash Conversion 90.75%
Profit Quality 141.63%
Current Ratio 1.05
Quick Ratio 0.5
Altman-Z 4.06
F-Score8
WACC9.19%
ROIC/WACC0.65
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
EPS Next Y21.28%
EPS Next 2Y21.44%
EPS Next 3Y22.34%
EPS Next 5Y18.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.78%
Revenue Next Year7.74%
Revenue Next 2Y9.23%
Revenue Next 3Y9.67%
Revenue Next 5Y10.84%
EBIT growth 1Y25.48%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y26.76%
FCF growth 1Y219.35%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.98%
OCF growth 3Y5.11%
OCF growth 5Y21.32%

SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.


Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.


How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for 56S1 stock?

The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 41.12 and the Price/Book (PB) ratio is 4.36.


What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?

The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 21.28% in the next year.